非流行区鼻咽癌:大型回顾性多中心队列中治疗强度的影响
该国际多中心回顾性研究分析2004至2017年11国36家医院连续鼻咽癌患者,比较非强化治疗(单纯放疗或同步放化疗)与强化治疗(同步放化疗前后加化疗)对生存的影响。全组5年总生存率84%、无病生存率65%,非强化治疗死亡或复发风险为强化治疗的1.37倍;强化治疗对无病生存的获益仅限于EBER阳性患者。
要点
- 非强化治疗者死亡或复发风险为强化治疗者的1.37倍。
- 诱导化疗+同步放化疗+IMRT者无病生存最优。
- 强化治疗对无病生存的获益仅见于EBER阳性患者。
核心结论
- 在低发病率地区,接受诱导化疗后同步IMRT放化疗的鼻咽癌患者无病生存率最高。
- 强化治疗对无病生存的获益仅限于EBER阳性患者,提示EBER阴性病例额外治疗无优势。
研究设计与样本
- 国际性、多中心、回顾性研究,纳入2004年至2017年11个国家36家医院的连续鼻咽癌患者。
- 总生存分析纳入1021例,无病生存分析纳入1113例;分别有501例和554例具备EBER状态。
- 治疗分为非强化治疗(单纯放疗或同步放化疗)和强化治疗(同步放化疗前和/或后加化疗)。
主要发现
- 全组5年总生存率为84%,5年无病生存率为65%。
- 非强化治疗者死亡或复发风险为强化治疗者的1.37倍。
- 接受非强化治疗者及接受诱导化疗+同步化疗+三维适形放疗者,死亡或复发风险分别为接受诱导化疗+同步放化疗+IMRT者的1.5倍和1.7倍。
- 强化治疗对总生存的影响在EBER阳性和EBER阴性患者中均未显示。
- 强化治疗在EBER阳性患者中显示更好的无病生存,在EBER阴性患者中未显示。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Recommendations for managing patients with nasopharyngeal carcinoma (NPC) in non-endemic areas are largely derived from studies conducted in endemic areas. We analysed the impact of treatment approaches on survival in non-endemic areas. METHODS: In an international, multicentre, retrospective study, we analyse consecutive patients with NPC diagnosed between 2004 and 2017 in 36 hospitals from 11 countries. Treatment was categorised as non-intensive (NIT), including radiotherapy alone or concomitant chemoradiotherapy (cCRT), and intensive (IT) including cCRT preceded by and/or followed by chemotherapy (CT). The impact of IT on overall survival (OS) and disease-free survival (DFS) was adjusted for all the available potential confounders. RESULTS: Overall, 1021 and 1113 patients were eligible for overall survival (OS) and disease-free survival (DFS) analyses, respectively; 501 and 554 with Epstein Barr-encoded RNA (EBER) status available. In the whole group, 5-year OS was 84% and DFS 65%. The use of NIT was associated with a risk of death or recurrence 1.37 times higher than patients receiving IT. Patients submitted to NIT and induction CT + concurrent concomitant chemo and three-dimensional Conformal Radiation Therapy (3DCRT) had a risk of death or recurrence 1.5 and 1.7 times higher than patients treated with induction CT + cCRT with intensity-modulated radiotherapy (IMRT), respectively. The IT had no impact on OS in neither patients with EBER+ nor in patients with EBER-; IT showed better DFS in EBER+ but not in patients with EBER-. CONCLUSIONS: In low-incidence areas, patients with NPC treated with induction CT followed by concurrent IMRT cCRT achieved the highest DFS rate. The benefit of IT on DFS was restricted to patients with EBER+, suggesting that additional therapy offers no advantages in EBER- cases.
引用
- Bossi P, Trama A, Bernasconi A, et al. Nasopharyngeal cancer in non-endemic areas: Impact of treatment intensity within a large retrospective multicentre cohort. Eur J Cancer. 2021. PMID: 34773903. doi:10.1016/j.ejca.2021.09.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。